Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
BioSpace
Merck's once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
pharminent
July 16, 2026 (Last updated: July 27, 2026)
BioSpace
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
